Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Rare Diseases

Prostatic Neoplasms

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Kennedy Disease

All Drugs and Chemicals

Androgens

Single agent dose escalation of AC176. AC176 will be given orally (PO) on a 28-day cycle.

AC176 will be given orally (PO) on a 28-day cycle.

AC176

This clinical trial is evaluating a drug called AC176 in participants with metastatic castration resistant prostate cancer (mCRPC) who have progressed on at least two prior systemic therapies.

The main goals of this study are to:

* Identify the recommended dose of AC176 that can be given safely to participants
* Evaluate the side effects of AC176
* Evaluate pharmacokinetics of AC176
* Evaluate the effectiveness of AC176

AC176-001 is a Phase I, first-in-human, open-label, multi-center dose-escalation study of AC176 given as a single agent. The AC176 is an investigational medicinal product that is a potent orally bioavailable Androgen Receptor (AR) degrader studied for the treatment of Metastatic Castration Resistant Prostate Cancer.

A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

A Phase I Study to Evaluate Safety, Tolerability, PK, Pharmacodynamics, and Preliminary Anti-Tumor Activity of AC176 in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Progressed on at Least Two Prior Systemic Therapies

Number of adverse events as characterized by type, frequency, seriousness, and relationship to AC176

Vital signs abnormalities as characterized by type, frequency, severity and timing

Laboratory abnormalities as characterized by type, frequency, severity and timing

Electrocardiogram (ECG) abnormalities such as heart rate, QTcF, PR, RR and QRS intervals

Accutar Biotechnology Inc

This clinical trial is evaluating a drug called AC176 in Chinese participants with metastatic castration resistant prostate cancer (mCRPC) who have progressed on at least one prior systemic therapy.

The main goals of this study are to:

Evaluate the safety and tolerability of AC176, evaluate pharmacokinetics and preliminary antitumor activity of AC176

AC176-002 is a Phase I, open-label, multi-center dose-escalation study of AC176 given orally as a single agent. The AC176 is an investigational medicinal product that is a potent orally bioavailable Androgen Receptor (AR) degrader studied for the treatment of patients with metastatic castration resistant prostate cancer.

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of AC176 in Chinese Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Vital signs abnormalities as characterized by type, frequency, severity and timing;

Laboratory abnormalities as characterized by type, frequency, severity and timing;

Electrocardiogram (ECG) abnormalities such as QTcF, PR, RR and QRS intervals

Area under the concentration-time curve over the dosing interval (AUC(0-tau))

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer	NCT05241613	Metastatic Cast...	AC176	18 Years -	Accutar Biotechnology Inc
A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer	NCT05673109	Metastatic Cast...	AC176	18 Years -	Accutar Biotechnology Inc

Spots Global Cancer Trial Database for ac176

Every month we try and update this database with for ac176 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for ac176

Every month we try and update this database with for ac176 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for ac176 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.